Riparian Pharmaceuticals Overview
- Founded
-
2012
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Series A2
- Latest Deal Amount
-
$3M
- Investors
-
9
Riparian Pharmaceuticals General Information
Description
Developer of pathophysiology therapeutics designed to improve endothelial function to reduce vascular complications. The company's therapeutics target new vasoprotective pathways to treat both prevalent and serious rare vascular diseases at an early stage, enabling physicians to have improved patient outcomes.
Contact Information
Website
www.riparianpharma.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Services
Biotechnology
Primary Office
- 201 Dexter Avenue
- Watertown, MA 02472
- United States
+1 (617) 000-0000
Riparian Pharmaceuticals Timeline
Riparian Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series A2) | 01-Apr-2021 | $3M | 000 | Completed | Generating Revenue | |
| 6. Later Stage VC (Series A1) | 12-Oct-2018 | 000 | 000 | 00.00 | Completed | Generating Revenue |
| 5. Accelerator/Incubator | 05-Oct-2017 | Completed | Generating Revenue | |||
| 4. Accelerator/Incubator | 13-Oct-2016 | Completed | Generating Revenue | |||
| 3. Grant | 06-Jun-2016 | 00000 | Completed | Generating Revenue | ||
| 2. Grant | 01-Jan-2016 | $2.83M | Completed | Generating Revenue | ||
| 1. Grant | 01-Jan-2013 | $857K | Completed | Startup |
Riparian Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 0,000,000 | 00.000000 | 00.00 | 00.0 | 00.0 | 00 | 00.0 | 0.000 |
Riparian Pharmaceuticals Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| William Adams Ph.D | Co-Founder, Chief Executive Officer, President & Board Member | ||
| Guillermo Garcia-Cardena Ph.D | Co-Founder & Scientific Advisor, Collaborator |
Riparian Pharmaceuticals Board Members (2)
| Name | Representing | Role | Since |
|---|---|---|---|
| Michael Serrano-Wu | Riparian Pharmaceuticals | Board Member | 000 0000 |
| William Adams Ph.D | Riparian Pharmaceuticals | Co-Founder, Chief Executive Officer, President & Board Member | 000 0000 |
Riparian Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Riparian Pharmaceuticals Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| JMCR Family Office | Family Office | Minority | 000 0000 | 000000 0 | |
| Sprout Bioventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Viva Biotech | Corporation | Minority | 000 0000 | 000000 0 | |
| Harvard Innovation Launch Lab | Accelerator/Incubator | 000 0000 | 000000 0 | ||
| Pagliuca Harvard Life Lab | Accelerator/Incubator | 000 0000 | 000000 0 |